Publications by authors named "M E Hegi"
Article Synopsis
- Glioblastoma recurrence remains unavoidable even after intensive treatments, with studies showing that targeting tumor-associated macrophages can reduce tumors and improve survival.
- However, around 50% of cases in long-term studies still saw recurrences linked to fibrotic scars, which form after multiple treatments.
- Research identified these fibrotic areas as protective environments for surviving cancer cells, and blocking the associated signaling pathways improved outcomes in preclinical trials of anti-CSF-1R therapy.
Background: The treatment of elderly/ frail patients with glioblastoma is a balance between avoiding undue toxicity, while not withholding effective treatment. It remains debated, whether these patients should receive combined chemo-radiotherapy with temozolomide (RT/TMZ→TMZ) regardless of the O6-methylguanine DNA methyltransferase gene promoter (MGMTp) methylation status. MGMT is a well-known resistance factor blunting the treatment effect of TMZ, by repairing the most genotoxic lesion.
View Article and Find Full Text PDFBrain metastasis (BrM) is a common malignancy, predominantly originating from lung, melanoma, and breast cancers. The vasculature is a key component of the BrM tumor microenvironment with critical roles in regulating metastatic seeding and progression. However, the heterogeneity of the major BrM vascular components, namely endothelial and mural cells, is still poorly understood.
View Article and Find Full Text PDFArticle Synopsis
- * A study looked closely at neutrophils in tumor tissues from patients with glioma (a type of brain cancer) and brain metastasis (cancer that has spread to the brain) and compared them to those in blood.
- * The researchers found that neutrophils in brain tumors are different from those in blood; they live longer and can help tumors grow by suppressing the immune response and causing inflammation.